Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bioverativ

- PMLiVE

Amgen beats Sanofi to PCSK9 inhibitor market

EC approval for Repatha gives it a lead over Praluent

EISAI

Eisai to transfer US manufacturing campus to Biogen

Willhand over Research Triangle Park facility incapacity-sharing deal

- PMLiVE

Brandicourt steers Sanofi onto a new heading

Unveilsmajor restructuring of the French pharma group

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Former Sanofi UK MD to head Teva UK

Steve Oldfield has been named as the firm’s new general manager

- PMLiVE

Praluent and Repatha backed for approval in US

Sanofi and Amgen remain in fierce competition in PCSK9 inhibitors

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

- PMLiVE

Sanofi rare disease drug a breakthrough, says FDA

Regulator awarded the status to olipudase alfa for metabolic disorder

- PMLiVE

IQWiG unimpressed with Tresiba for children

German cost watchdog says Novo’s insulin may in fact cause more harm in certain patients

- PMLiVE

Shire launches rare disease website

Hereditary angioedema sitesupports its Me, Not HAE campaign

- PMLiVE

Sanofi pays $245m for FDA priority review voucher

PRV reduces review time from ten to six months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links